Teleflex Incorporated (NYSE:TFX)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group LLC in a research note issued on Wednesday. They currently have a $253.00 price target on the medical technology company’s stock, up from their previous price target of $230.00. Jefferies Group LLC’s price target points to a potential upside of 18.78% from the stock’s previous close. Jefferies Group also issued estimates for Teleflex’s Q3 2017 earnings at $1.99 EPS, FY2017 earnings at $8.22 EPS, Q1 2018 earnings at $2.12 EPS, Q2 2018 earnings at $2.39 EPS, Q3 2018 earnings at $2.44 EPS, Q4 2018 earnings at $2.70 EPS, FY2019 earnings at $10.98 EPS and FY2020 earnings at $12.39 EPS.

Other equities research analysts have also issued research reports about the stock. BidaskClub lowered shares of Teleflex from a “hold” rating to a “sell” rating in a report on Tuesday. Zacks Investment Research lowered shares of Teleflex from a “buy” rating to a “hold” rating in a report on Saturday, May 20th. Leerink Swann boosted their price target on shares of Teleflex from $215.00 to $220.00 and gave the company a “market perform” rating in a report on Friday, June 9th. Needham & Company LLC reissued a “buy” rating and issued a $224.00 price target on shares of Teleflex in a report on Friday, May 5th. Finally, Deutsche Bank AG boosted their price target on shares of Teleflex from $213.00 to $220.00 and gave the company a “buy” rating in a report on Monday, May 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $228.00.

Teleflex (NYSE:TFX) traded down 1.06% on Wednesday, hitting $210.75. 57,814 shares of the stock were exchanged. The company’s 50 day moving average is $207.61 and its 200 day moving average is $195.00. The stock has a market cap of $9.48 billion, a PE ratio of 43.74 and a beta of 1.05. Teleflex has a 1-year low of $136.53 and a 1-year high of $216.37.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.91 by $0.13. The firm had revenue of $528.60 million for the quarter, compared to analyst estimates of $518.98 million. Teleflex had a net margin of 12.36% and a return on equity of 16.12%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.89 EPS. On average, equities research analysts expect that Teleflex will post $8.25 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Teleflex’s (NYSE:TFX) “Buy” Rating Reiterated at Jefferies Group LLC” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/08/09/teleflexs-nysetfx-buy-rating-reiterated-at-jefferies-group-llc.html.

In other news, Director Stephen K. M.D. Klasko sold 5,200 shares of the business’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $193.56, for a total value of $1,006,512.00. Following the sale, the director now owns 12,880 shares in the company, valued at approximately $2,493,052.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stephen K. M.D. Klasko sold 200 shares of the business’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $199.93, for a total transaction of $39,986.00. Following the completion of the sale, the director now owns 8,080 shares in the company, valued at approximately $1,615,434.40. The disclosure for this sale can be found here. Insiders sold a total of 8,300 shares of company stock worth $1,643,975 in the last 90 days. 2.39% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of TFX. Marshall Wace North America L.P. raised its stake in Teleflex by 137.4% in the second quarter. Marshall Wace North America L.P. now owns 518,462 shares of the medical technology company’s stock valued at $107,840,000 after buying an additional 300,069 shares during the last quarter. Principal Financial Group Inc. raised its stake in Teleflex by 93.5% in the second quarter. Principal Financial Group Inc. now owns 610,398 shares of the medical technology company’s stock valued at $126,816,000 after buying an additional 294,935 shares during the last quarter. FMR LLC raised its stake in Teleflex by 46.5% in the first quarter. FMR LLC now owns 811,764 shares of the medical technology company’s stock valued at $157,263,000 after buying an additional 257,649 shares during the last quarter. MARSHALL WACE ASIA Ltd acquired a new stake in Teleflex during the first quarter valued at about $42,368,000. Finally, Vanguard Group Inc. raised its stake in Teleflex by 5.2% in the first quarter. Vanguard Group Inc. now owns 3,781,475 shares of the medical technology company’s stock valued at $732,584,000 after buying an additional 186,845 shares during the last quarter. Institutional investors own 93.02% of the company’s stock.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Analyst Recommendations for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.